Browsing: Medicine

The FDA approved Roche’s Wilserdly (giredestrant) on November 16 for adults with ER-positive, HER2-negative advanced breast cancer that carries an ESR1 mutation and has progressed after hormone therapy. The once-daily pill is taken with the cancer drug everolimus, creating an all-oral regimen. In the phase 3 evERA trial, the combination cut the risk of disease progression or death by 62% in patients with ESR1 mutations. Patients need an FDA-authorized test to confirm the mutation, which affects up to 40% of people with hormone receptor-positive metastatic breast cancer. A separate FDA decision on use after surgery for early-stage disease is expected by November 30.

The FDA has approved Sunharbo (asundexian), Bayer’s once-daily pill to lower the risk of another stroke in adults who recently had a mild-to-moderate ischemic stroke or a high-risk mini-stroke. It is the first approved factor XIa inhibitor, a new type of blood thinner designed to stop harmful clots while limiting bleeding. The approval rests on the OCEANIC-STROKE trial of 12,327 patients, which found fewer repeat strokes without a significant rise in major bleeding. Sunharbo is taken alongside standard antiplatelet medicines. Doctors welcomed the option but say cost and insurance access could slow early use.